PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Takeda Consumer Healthcare Looks to Stable, Sustainable Growth: President
June 13, 2017
- PeptiDream Licenses Peptide Discovery Platform to Shionogi
June 13, 2017
- Mochida, Ayumi Hook Up on Sales of Enbrel, Humira Biosimilars
June 13, 2017
- Kissei Gets Japan Rights to Avacopan for Rare Kidney Diseases
June 12, 2017
- Lurasidone Beats Primary Endpoint in Bipolar I Depression: Sumitomo Dainippon
June 12, 2017
- Astellas/Pfizer Amend Xtandi Trial Protocol, Topline Data Due Out This Year
June 12, 2017
- Alcohol Dependence Med Nalmefene Delivers Positive Japan Data: Otsuka/Lundbeck
June 9, 2017
- Pediatric Ozex Generics of Takata, Meiji Now Have Same Indications as Originator
June 8, 2017
- 3 Japan Generic Majors See Decelerating Growth in FY2016: Jiho Tally
June 8, 2017
- FDA Accepts Sawai’s ANDA for Tecfidera Generic
June 8, 2017
- Daiichi Sankyo’s DS-8201 Yields 40.2% ORR in HER2-Expressing Solid Tumors: PI
June 7, 2017
- CSL Japan Chief Anticipates Annual Sales of 40 Billion Yen in Midterm Business Plan Achievable
June 7, 2017
- Pfizer Boosting Global Oncology Footprint with Diverse Portfolio: SVP
June 7, 2017
- PII Data Updated for Sumitomo Dainippon’s Napabucasin
June 6, 2017
- Details Revealed for Lenvima’s Non-Inferiority Study vs Nexavar in 1st Line HCC
June 6, 2017
- Linzess Most Heavily Promoted for GPs in Launch Month of March: Anterio
June 6, 2017
- Discontinuation of Development Continues for Novel Diabetes Drugs, Including Daiichi Sankyo’s GPR119 Agonist
June 6, 2017
- Astellas, Kyoto Univ. Launch New 3-Year Joint Project
June 5, 2017
- AbbVie to Seek Indication Expansions for Humira, Competing with Biosimilars on the Strength of Original Product’s Reliability
June 5, 2017
- Sugino Appointed President of Amgen Astellas
June 2, 2017
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…